|View printer-friendly version|
|October 31, 2017 9:52 a.m.|
|Teva Wins Generic Uceris® Patent Trial|
“We are pleased to have another legal win on one of our first-to-file
PIV patent challenges brought in through the Actavis Generics
Based on available information, Teva believes it is a "first applicant" to file an ANDA for the generic version of Uceris®. Should its ANDA be approved, Teva may be entitled to 180 days of generic market exclusivity.
Uceris® had annual sales of approximately
With nearly 600 generic medicines available, Teva has the largest
Teva's Safe Harbor Statement under the
This press release contains forward-looking statements, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 20-F for the
Teva Pharmaceutical Industries Ltd.